Key result
Metabolic-associated fatty liver disease was independently associated with a higher prevalence of noncalcified coronary plaques (OR 1.67) and mixed plaques (OR 1.54) compared to patients without the disease.
Why the study?
Since NAFLD was renamed MAFLD in 2020, no studies have evaluated the correlation between MAFLD and coronary atherosclerosis.
Does metabolic-associated fatty liver disease (MAFLD) correlate with coronary atherosclerosis and high-risk plaque patterns?
Population
1164 patients undergoing continuous CCTA and abdominal ultrasound during routine physical examination
Comparison
MAFLD vs non-MAFLD
Design
Cross-sectional study
Authors
Loading...
MAFLD may flag higher-risk patients; hypothesis-generating and should not yet change practice.
Cross-Sectional (n=1,164)
No
Does metabolic-associated fatty liver disease (MAFLD) correlate with coronary atherosclerosis and high-risk plaque patterns?
Odds Ratio: 1.67 (95% CI 1.15–2.43)
Absolute Event Rate: 21.18% vs 12.81%
p-value: p=0.007
MAFLD is independently associated with high-risk coronary plaque patterns (noncalcified and mixed plaques), suggesting a need for early ASCVD screening in this population.
Zhang et al. (2023) conducted a cross-sectional in Metabolic-associated fatty liver disease (MAFLD) and coronary atherosclerosis (n=1,164). Metabolic-associated fatty liver disease (MAFLD) vs. Non-MAFLD was evaluated on Presence of noncalcified coronary plaques (OR 1.67, 95% CI 1.15-2.43, p=0.007). Metabolic-associated fatty liver disease was independently associated with a higher prevalence of noncalcified coronary plaques (OR 1.67) and mixed plaques (OR 1.54) compared to patients without the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: